Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Overweight from Neutral at JPMorgan with analyst Chris Schott saying new products could drive upside to 2017 estimates while the risk/reward is favorable into solanezumab data late this year. 2. Johnson Controls (JCI) upgraded to Outperform from Neutral at Macquarie with analyst Mike Wood saying he has increased confidence on the commercial recovery, upside to Tyco synergies, improving cash flow, and potential for further portfolio simplification. 3. Sanofi (SNY) upgraded to Buy from Hold at Berenberg. 4. VMware (VMW) reinstated with Overweight from Neutral at JPMorgan with analyst Mark Murphy saying partner interviews highlight strength in the company's products and Dell has publicly stated that its global distribution network can lead to $1B of incremental VMware revenue. 5. Volaris (VLRS) upgraded to Overweight from Equal Weight at Morgan Stanley. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

Volaris is up 13.7%, or $1.09 to $9.12.

Sees FY24 EBITDAR margin 32%-34%. Sees FY24 capital expenditures $400M. Sees FY24 average jet fuel price $2.60-$2.70.